The 14 most recent market catalysts affecting $RGNX, each scored for sentiment and estimated stock impact. Sourced from SEC EDGAR filings and financial news, analysed automatically as they are published.
Sep 25, 2026
Corporate Catalyst
Bullish
Impact 75
Reported Earlier, REGENXBIO Presents Three-Year Sura-Vec Data Showing Majority Of NPDR Participants Achieved Greater Than 2-Step DRSS Improvement, No Vision-Threatening Events
REGENXBIO reported compelling three-year data for its sura-vec gene therapy in NPDR patients. The key takeaway is that a majority of participants achieved significant improvement w…
Sep 23, 2026
Corporate Catalyst
Bullish
Impact 65
REGENXBIO Says All Ongoing Patent Litigation Regarding Patents-In-Suit To Be Terminated With Prejudice; Agrees Not To Sue Sarepta Or Affiliates Over Existing Elevidys Or AAVrh74-Based Capsids
REGENXBIO and the University of Pennsylvania have settled their patent infringement lawsuit against Sarepta Therapeutics and Catalent. Sarepta will pay REGENXBIO $39 million, and a…
Aug 25, 2026
Corporate Catalyst
Bearish
Impact 55
Baird Maintains Outperform on Regenxbio, Lowers Price Target to $29
Baird analyst Brian Skorney maintained an 'Outperform' rating on Regenxbio, signaling continued confidence in the company's fundamentals and future growth. However, the price targe…
Aug 24, 2026
Corporate Catalyst
Bearish
Impact 85
Regenxbio Hits Regulatory Roadblock After FDA Puts RGX-121 on Hold
Regenxbio's investigational gene therapy, RGX-121, for Hunter Syndrome has been placed on clinical hold by the FDA. This decision stems from the discovery of asymptomatic spine MRI…
Aug 24, 2026
Corporate Catalyst
Bearish
Impact 85
REGENXBIO shares are trading lower after the company announced that the FDA placed a clinical hold on RGX-121 following the discovery of asymptomatic spine MRI findings in five participants in the CAMPSIITE study
The FDA clinical hold on RGX-121 is a significant negative catalyst for REGENXBIO (RGNX) as it directly impacts their lead gene therapy candidate for MPS II. The discovery of asymp…
Aug 24, 2026
Corporate Catalyst
Bearish
Impact 95
REGENXBIO Says FDA Placed Clinical Hold On RGX-121 For Hunter Syndrome After Asymptomatic Spine MRI Findings In Five CAMPSIITE Participants; Does Not Expect To Resubmit BLA In Near Term
The FDA's clinical hold on RGX-121, a crucial gene therapy for Hunter Syndrome, is a severe blow to REGENXBIO. The 'asymptomatic spine MRI findings' raise safety concerns, and the …
Aug 24, 2026
Corporate Catalyst
Neutral
Impact 85
The FDA Places Clinical Hold On Regenxbio's RGX-121 Following Asymptomatic Spine MRI Findings In Five Participants In CAMPSIITE Study In Mucopolysaccharidosis Type II Patients
REGENXBIO announced that the FDA has placed a clinical hold on its investigational gene therapy, RGX-121, for Mucopolysaccharidosis type II (Hunter Syndrome). This decision follows…
Aug 6, 2026
Corporate Catalyst
Bullish
Impact 92
Regenxbio Q2 EPS $0.43 Beats $(0.03) Estimate, Sales $108.019M Miss $117.127M Estimate
Regenxbio's Q2 earnings report presents a mixed picture for investors. The significant beat in EPS, turning a projected loss into a profit, is a strong positive signal, indicating …
Jul 20, 2026
Corporate Catalyst
Bullish
Impact 85
Clinical Trial Results Show Extended Benefits for REGENXBIO Retinal Treatments
REGENXBIO (RGNX) released compelling long-term data for its gene therapy, surabgene lomparvovec, demonstrating sustained visual benefits and reduced injection frequency for wet AMD…
Jul 20, 2026
Corporate Catalyst
Bullish
Impact 75
Reported Saturday, REGENXBIO Presents Favorable Long-Term Data For Sura-Vec Showing Stable To Improved Vision Through 5 Years In Wet AMD And 2.5-Year Efficacy In Diabetic Retinopathy At ASRS Annual Meeting
This headline represents a significant corporate catalyst for REGENXBIO (RGNX) due to the positive long-term clinical data for Sura-Vec. Favorable results in large markets like Wet…
Jul 17, 2026
Corporate Catalyst
Bearish
Impact 75
REGENXBIO shares are trading lower after the company announced the pricing of its offering of 10,003,889 shares at $9.00 per share and 1,111,111 pre-funded warrants at $8.9999 per warrant.
The primary impact of this announcement is a negative one for REGENXBIO (RGNX) shareholders due to the immediate dilution of their holdings. Companies typically undertake such offe…
Jul 17, 2026
Corporate Catalyst
Neutral
Impact 75
REGENXBIO Prices Offering Of 10,003,889 Shares At $9.00 Per Share And 1,111,111 Pre-Funded Warrants At $8.9999 Per Warrant
REGENXBIO announced the pricing of a public offering of 10,003,889 shares of common stock at $9.00 per share and 1,111,111 pre-funded warrants at $8.9999 per warrant, expecting to …
Jul 16, 2026
Corporate Catalyst
Bearish
Impact 85
REGENXBIO shares are trading lower after the company announced a $100 million offering.
The $100 million offering by REGENXBIO is a significant corporate catalyst, directly impacting its stock price due to the immediate dilution of existing shares. Companies typically…
Jul 16, 2026
Corporate Catalyst
Neutral
Impact 75
REGENXBIO Plans To Commence $100M Common Stock Offering
REGENXBIO is planning to raise $100 million through a common stock offering, which is a significant capital infusion for the company. This move is typical for biotechnology firms t…
Not financial advice. AI-generated analysis for informational purposes only. Tradow AI LLC is not a registered investment adviser.